BioBlast w/e 03 Mar 23:

Biospectrum India reported that Enzene Biosciences has launched its adalimumab (biosimilar to AbbVie’s Humira®) in India for the treatment of…

Related Keywords

China ,Reykjavik ,C10 ,Iceland ,India ,South Korea ,West Virginia ,United States ,South Korean ,Amgen Stelara ,Enzene Biosciences ,Samsung Biologics ,Johnson Stelara ,Genentech Herceptin ,Samsung Bioepis ,Robert Wessman ,Abbvie Humira ,Celltrion Samsung Bioepis ,Seo Jung Jin ,Amgen ,Us District Court Of Delaware ,Us District Court ,District Court ,Samsung ,Pfizer ,Us Janssen Biotech Inc ,National Medical Products Administration ,Cn Eisai Co ,Celltrion Group ,Janssen Biotech Inca Johnson ,Immune Thrombocytopenic Purpura ,Priority Review ,Janssen Biotech ,Court Judge Noreika ,Judge Noreika ,Retired Celltrion ,Korea Biomedical Reviewhas ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Australia ,Ealthcare Amp Life Sciences ,